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| INTRODUCTION
The incidence of venous thromboembolism (VTE) is about 7-to 28-fold higher in cancer patients as compared to non-cancer patients, making it an important contributor to morbidity and the second leading cause of mortality, accounting for 9% of deaths in cancer patients. [1] [2] [3] [4] Cancer patients with VTE not only have a significant increase in the frequency and duration of hospitalizations, but also a delay in cancer-directed therapy which can often lead to increased overall healthcare costs and financial toxicity. 5 VTE in cancer patients is mostly diagnosed based on presenting symptoms or through incidental findings at the time of staging or surveillance imaging. There is a substantial variation in risk of VTE between individual cancer patients. 6 Current guidelines from the American Society of Clinical Oncology (ASCO) recommend utilizing a validated risk tool for formal risk assessment. 7 Recent data have shown that high-risk patients are at a heightened risk of VTE and screening such patients with compression ultrasonography may identify subclinical VTE. 2, [8] [9] [10] [11] Since both screen-detected and incidental VTEs are identified based on imaging rather than symptoms, therapeutic anticoagulation is likely to be beneficial in both settings, although the evidence to support this is primarily for incidental pulmonary embolism (PE) and not for incidental deep vein thrombosis (DVT). Current guidelines also recommend that a screen-detected ("incidental") VTE be treated the same as symptomatic VTE. 7 A prior healthcare process innovation project at Ottawa Hospital Regional Cancer Center utilized the Khorana score to identify high-risk patients and target them for greater education regarding risk of VTE. 12 However, utilizing such an electronic alert of high-risk patients for screening or early detection has not been formally evaluated in a clinical setting.
The purpose of this study was to create an automated alert system for early detection of VTE in high-risk cancer patients (as defined by the Khorana score) through lower extremity ultrasonography screening in the ambulatory setting. We developed and implemented an automated alert in the electronic medical record and evaluated rates of subsequent VTE, compliance with screening recommendations, and rate of subsequent VTE in unscreened patients.
| METHODS
We developed a novel electronic medical record alert to identify consecutive ambulatory cancer patients at increased risk for VTE based on the Khorana score. 3 We chose this score as it was the only validated risk tool in this setting at the time and remains the only one recommended by multiple guidelines. The alert was integrated into the electronic health record (EPIC) of Cleveland Clinic. The study was approved by the Institutional Research Ethics Committee. The requirement for informed consent was waived as this was a pilot study for better utilization of an already validated risk tool recommended by national guidelines. This pilot study was conducted exclusively at Taussig Cancer Center at the main campus of Cleveland Clinic from August 2016 through January 2018. All providers were educated regarding the pilot at scheduled physician and advanced practice provider meetings. This information was also distributed by the institute's monthly e-newsletter.
| Patient eligibility
Patient eligibility was determined upon histological or cytological confirmation of a cancer diagnosis with targeted enrollment for specific tumor types (gastric, pancreatic, lung, lymphoma, bladder, and testicular) in the initial silent phase and later expanded to all tumor types in the active phase of the study. Diagnoses were identified through ICD-9 codes by disease group clusters, which were manually screened to remove any diagnoses within those clusters that
were not appropriate for a KS of 1 or 2. Inclusion required patients to be at least 18 years of age with a follow-up visit after diagnosis of active malignancy. Patients were excluded if (a) they had primary gynecologic malignancy (due to geographic distribution of ambulatory clinics); (b) they had a confirmed VTE within 3 months prior to diagnosis; or, (c) they were receiving therapeutic anticoagulation for any other medical indications (eg, arterial embolism, left ventricular thrombus, atrial fibrillation, pulmonary hypertension).
| Identification of patients at risk for VTE
The automated alert used five risk factors that were independently predictive of symptomatic VTE in cancer patients. 
Essentials
• Cancer outpatients are at risk for thrombosis which can lead to urgent visits and hospitalization.
• An electronic alert was built to identify high-risk patients and suggest screening for early detection.
• Of screened patients, 12.5% had deep vein thrombosis and were anticoagulated.
• Screening ultrasonography in high-risk cancer patients deserves further study to facilitate early detection. 
| Follow-up
Patients from both phases were followed for 3 months following their initial alert date or until date of death. Patients were excluded if lost to follow-up within 90 days of alert. A confirmatory ultrasound was required for diagnosis of DVT.
| Data collection and study end points
The primary end-point was to describe acute-appearing proximal or distal DVT rates in active phase patients within the high-risk Descriptive statistics were used to present patient baseline characteristics; Kaplan-Meier failure function was used to estimate cumulative incidence of VTE.
| RESULTS

| Silent phase
During the silent phase, the alert screened 194 consecutive patients with the six oncologic diagnoses listed below, and risk stratified by KS, with median age of 63 years and 54% males. The most prevalent cancer types were lung (23.2%) and pancreatic (21.6%) cancers. Other malignancies included bladder, lymphoma, gastric, and testicular cancers ( Figure 1 ).
TA B L E 1 Silent and active phase patient characteristics
None of the 50 patients with a KS of 1 developed DVT during the 90-day follow up. There were no patients with a score of 0 given that the silent phase was limited to higher risk oncology tumor types described by KS. No patient was lost to follow-up in the silent phase of the study, and 33 patients had expired during the 90-day period (Tables 2 and 3 ). Seven of the 13 DVT events in the silent phase were proximal thrombi, and two of three PE in this phase were segmental while one was subsegmental. The median time from alert to DVT and PE were 27 and 66 days, respectively. Of patients diagnosed with a DVT, 54.5% were identified during their initial or second clinic visit by an oncology provider. The cumulative incidence of VTE in this phase is shown 
| Active phase
In the active phase, 233 patients were identified as high risk by the computerized alert system during the 6-month pilot screening period. Of these, 36 were excluded from analysis because they were already on therapeutic anticoagulation or had a recent history of VTE diagnosis. Only three patients were lost to follow-up.
Of the remainder (N = 197), the alert was accepted and screening lower extremity ultrasonography ordered on 40 patients (20.3%).
Of these, five (12.5%) were found to have a lower extremity DVT and were all started on therapeutic anticoagulation. Of the remaining 157 patients that had alerts but were not screened, 13 (8.3%)
were later diagnosed with symptomatic DVT after a median period of 50.5 days (0-85) from the date of clinical alert ( Figure 2 ). Of these 13 non-screened patients, six patients (46.2%) were diagnosed with a symptomatic DVT within 30 days of their alert, and eight patients (61.5%) were diagnosed within 60 days (Table 3) . Four patients with DVT also had PE. The cumulative incidence of VTE in the alerted but unscreened patients of the active phase is shown in Table 4 . The seven (4.5%) additional non-screened patients were diagnosed with a PE (median time from alert of 43 days ). There were a total of 25 (12.7%) individual VTE events during active phase analysis of all screened and unscreened patients with an alert. Two of the five screened patients, while six of the 13 unscreened patients exhibited proximal lower extremity thrombi, while the rest had distal thrombi.
Six of seven PE events were segmental thrombotic events, while one was subsegmental. Finally, 35 of 40 patients who did not have DVT on screening remained without documented VTE events during the 90-day follow-up period.
| DISCUSSION
In this real-world clinical practice study, we demonstrate that creating an electronic health record alert to identify cancer patients at risk of DVT (based on a validated risk tool) is feasible, and impacts clinician behavior. We additionally demonstrate that suggesting the use of screening ultrasonography leads to identification of preexisting DVT in a significant portion of patients undergoing active cancer directed therapy. Our findings suggest that the use of electronic health record (EHR) alerts could lead to earlier detection of VTEs and treatment with anticoagulants.
In our study, the identified rates of DVT on screening US were higher than previously reported rates of around 9% on baseline screening (which included CT chest). 10 This may be related to the known higher "real-world" rates compared to patients on clinical trials, which were the basis of the two prior reports. 10, 13 Our rates were similar to a prior clinical practice study at Ottawa Hospital Regional Cancer
Center, although that study expanded the definition of high-risk to a score of 2 or higher. 12 It should be noted that there was a low rate of ordering the suggested screening ultrasonography, and it is possible that the clinicians use of additional discretion in determining risk of subclinical VTE beyond the electronic alert may have contributed to this higher than expected rate. 6, 14, 15 We also observed that 8.3% of the patients who had their suggested ultrasound order deferred, subsequently developed a symptomatic DVT. The active phase alerted patient population that were eligible but not screened accounted for 13 symptomatic DVTs and an additional seven PE events during the 90-day period. As opposed to this, none of the 35 patients with a confirmed negative screening ultrasound (of the 40 screened patients) had a documented DVT or PE during the 90-day follow-up period.
This suggests that many of the 13 diagnosed DVTs could have been diagnosed by screening ultrasound on index alert prior to developing the signs/symptoms that subsequently required a diagnostic study.
Further, it is possible that some PE events could have been avoided with early detection of DVT and institution of anticoagulation.
One finding of our study was low provider compliance to accept the suggested screening order, as only 20% of alerted high-risk patients received ultrasonography. This is not unexpected given that the recommendation for screening was only a suggestion and not a mandate in this pilot study. We believe behavior may change with available data from this pilot supplemented by additional validation studies. The compliance may also have been limited by patient deferral due to time constraints of their clinical visit or disrupting patient schedules for those with additional appointments on the day of their alert encounter.
Our study certainly had several limitations. One limitation is the timing of the alert. Our current electronic medical record (EMR) does not clearly define a "pre-chemotherapy" visit and so we were unable to devise the alert to fire during a specific time period. Future iterations of the alert or of the EMR may allow us to do so. Another limitation is that we are potentially over-treating cancer patients with screen-detected DVTs. However, unlike other settings, cancer is a TA B L E 4 Incidence of VTE in silent phase (n = 194), and active phase with deferred ultrasound screening (n = 157) ticipated, there appears to be a tangible benefit for early detection in lower-extremity DVTs. Our alert thus far only "suggests" an ultrasound, but this could be altered in future iterations to a stronger "recommendation." We plan to further focus on provider education by dissemination of internal data to improve compliance and increase acceptance of the automated alert system. However, "alert fatigue" can be an issue with provider compliance and needs to be addressed in future plans.
16
Moving forward, we believe our findings are particularly relevant in the context of two ongoing trials of thromboprophylaxis-CASSINI and AVERT. 17, 18 While both studies are evaluating the benefit of thromboprophylaxis in high-risk patients (defined as KS ≥ 2), the study design of CASSINI introduces a baseline ultrasound prior to randomization whereas AVERT does not. Data from these studies should further clarify the benefit of screening ultrasonography in high-risk cancer patients. Given that these screening techniques rely on parameters widely available electronically on most cancer patients, these alerts should be easy to implement if the available data continues to demonstrate benefit for patients, therefore and would allow early detection approaches to complement successful prophylaxis strategies in the future. As the project is currently ongoing with full support from the institutional leadership, we plan to revisit provider education during department staff meetings incorporating these data. Our approach may also be affected based on, results from ongoing prophylaxis studies.
In conclusion, in a pilot study at a large academic cancer center, we were able to successfully introduce an electronic medical alert that identified cancer patients at high risk for VTE. When appropriately utilized, this alert led to early detection of lowerextremity DVT, providing the potential to avoid urgent visits and hospitalizations due to subsequent symptomatic events, including PE. Further studies are needed to increase compliance with the alert and to more completely evaluate its impact on clinical outcomes.
